- Investor Relations
German Cancer Research Center (DKFZ) in Heidelberg and PHI have signed a collaboration agreement, to foster the use of HoloMonitor technology at DKFZ. A HoloMonitor M4 with a motorized XY-stage will be centrally installed at the Imaging and Cytometry Core Facility and made available to the over 1 000 cancer researchers at DKFZ.
“DKFZ is one of the leading cancer research centers in Europe, if not the leading. Our strategy is to continue to demonstrate the benefits of HoloMonitor technology with leading research institutions and key opinion leaders on the forefront of cancer research. A key goal for PHI is to establish 8 strategic partnerships with leading research institutions before the end of 2015. With this agreement, 6 such agreements have now been signed”, says CEO Peter Egelberg.